ERAS - Erasca Inc

https://www.erasca.com

Buy Momentum: Bearish

Recent News

This Accenture Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Accenture ( NYSE:ACN ) , Academy Sports ( NASDAQ:ASO )

Benzinga • 1 week, 4 days ago • score: 0.12

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. B of A Securities analyst Alec Stranahan downgraded Erasca, Inc.

Neutral

Erasca Narrows Loss 46% in Fiscal Q2

Motley Fool • 1 month ago • score: 0.08

Erasca ( NASDAQ:ERAS ) , a clinical-stage biotechnology company focused on developing cancer therapies targeting the RAS/MAPK pathway, released its second quarter results on August 12, 2025. The company highlighted accelerated progress for two key clinical programs and reported operating expenses ...

Neutral

Erasca to Present at Upcoming Investor Conferences in June

GlobeNewswire • 3 months, 2 weeks ago • score: 0.02

SAN DIEGO, May 29, 2025 ( GLOBE NEWSWIRE ) -- Erasca, Inc. ( Nasdaq: ERAS ) , a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will ...

Neutral

Erasca to Present at the Bank of America Securities Health Care Conference

GlobeNewswire • 4 months, 1 week ago • score: 0.10

SAN DIEGO, May 07, 2025 ( GLOBE NEWSWIRE ) -- Erasca, Inc. ( Nasdaq: ERAS ) , a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank ...

Neutral

Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting - Erasca ( NASDAQ:ERAS )

Benzinga • 4 months, 2 weeks ago • score: 0.07

ERAS-0015 and ERAS-4001 showed robust anti-tumor activity as monotherapy and combination therapy First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling

Bullish

This Spotify Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Shake Shack ( NYSE:SHAK ) , Erasca ( NASDAQ:ERAS )

Benzinga • 5 months, 2 weeks ago • score: 0.33

Neutral

Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting

GlobeNewswire • 5 months, 2 weeks ago • score: 0.04

Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

None

52W High

$3.31

52W Low

$1.01

MA Status:

50D: Above 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.09

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-1.57

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

1.23

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

11.68%

Institutions (25–75% balanced)

81.93%

Shares Outstanding

283,670,000

Float

167,459,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-0.39

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.31%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.0161

0.0182

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025